Skip to Main Content

Paper Details

Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
J Natl Cancer Inst
8
2022
BRCA1, BRCA1 and 2, BRCA1 and 2 mutation, BRCA1 and BRCA2, BRCA1 mutation, BRCA2, BRCA2 Mutation, BRCA2 mutation, COCP, COCP-associated (breast, ovarian, endometrial) cancer, COCP-associated cancer, Cancer, Triple-negative breast cancer, breast cancer, breast, ovarian, and endometrial cancer, cancer, ovarian and endometrial cancer, women
Author NameAffiliation
Douglas F EastonUniversity of Cambridge
Douglas F EastonUniversity of Cambridge
David E GoldgarUniversity of Utah School of Medicine
David E GoldgarUniversity of Utah School of Medicine
Esther M JohnStanford Cancer Institute, Stanford University School of Medicine
Roger L Milne
Roger L MilneThe University of Melbourne
Roger L MilneSchool of Clinical Sciences at Monash Health, Monash University
Mary Beth TerryColumbia University
  • 1 - 9

Datasets

Release 1.2